Telomir Pharmaceuticals Inc. Common Stock (TELO)

About TELO

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

telomirpharma.com/

Fundamentals

1-day range

$1.14$1.2

Market cap

$80.47M

P/E (trailing)

—

P/E (forward)

-4.07

EPS (trailing)

$-0.29

Dividend yield

—

Beta

-0.21

Avg. volume

100.7K

Telomir Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TELO

  Telomir Pharmaceuticals Inc. Common Stock

  $1.14

  ▼ 4.20%
  Market cap $80.47MP/E —
  $0.8884$2.09
• MAIA

  MAIA Biotechnology Inc. Common Stock

  $1.33

  ▼ 3.99%
  Market cap $80.26MP/E —
  $0.87$3.19
• ATHE

  Alterity Therapeutics Limited American Depositary Shares

  $4.51

  ▼ 1.10%
  Market cap $80.78MP/E —
  $0.01$0.785
• NMAD

  Nomad Power Solutions Inc. Common Stock

  $4.33

  ▼ 2.04%
  Market cap $81.57MP/E —
  $3.12$7.7
• LFVN

  Lifevantage Corporation Common Stock (Delaware)

  $6.6

  ▲ 2.33%
  Market cap $83.01MP/E 14.23
  $3.9$14.28
• GANX

  Gain Therapeutics Inc. Common Stock

  $1.78

  ▼ 3.78%
  Market cap $74.64MP/E —
  $1.53$4.34
• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $86.38MP/E —
  $6.01$17.44

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
  Yahoo · 8/10/2026
• 12 Health Care Stocks Moving In Tuesday's After-Market Session
  Benzinga · 8/4/2026

• Aminov Erez · May 21, 2026 · Disposition

  2.00M
• Aminov Erez · May 21, 2026 · Grant

  2.00M
• Aminov Erez · May 21, 2026 · Disposition

  1.96M
• Aminov Erez · May 21, 2026 · Grant

  1.96M
• Whalen Matthew Pratt · May 21, 2026 · Disposition

  25.0K
• Whalen Matthew Pratt · May 21, 2026 · Grant

  25.0K
• MacPherson Edward Clouston · May 21, 2026 · Disposition

  25.0K
• MacPherson Edward Clouston · May 21, 2026 · Grant

  25.0K
• Del Giudice Matthew Paul · May 21, 2026 · Disposition

  25.0K
• Del Giudice Matthew Paul · May 21, 2026 · Grant

  25.0K
• Aminov Erez · April 22, 2026 · J

  7.32M @ $1.37
• Whalen Matthew Pratt · April 16, 2026 · Grant

  50.0K
• Del Giudice Matthew Paul · April 16, 2026 · Grant

  50.0K
• MacPherson Edward Clouston · April 16, 2026 · Grant

  50.0K

Institutional Ownership

March 31, 2026

Total shares held

2.10M

Total value held

$2.73M

Institutional holders

24